NewsFeed Voices Science Insight Innovation
January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Christopher Cannon/LinkedIn
Oct 3, 2025, 11:50

Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events

Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:

”Late-breaking news!!!

PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”

Read the full article here.

Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients

Christopher Cannon on Evolocumab - Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events

Stay updated on the latest scientific breakthroughs with Hemostasis Today.

Amgen Cardiovascular Primary Prevention Christopher Cannon Evolocumab FOURIER Health Hematology Hemostasis Hemostasis Today Medicine PCSK9 inhibition thrombosis
NewsFeed